Which is better, TB-500 or GHK-Cu?
GHK-Cu is graded human observational on the strength of controlled topical cosmetic studies, and topical products are lawful without a prescription. Injected TB-500 is graded animal only; the one human randomized trial of thymosin beta-4 used eye drops for dry eye and did not meet its primary endpoints. On regulatory status TB-500 is a step ahead for injection (PCAC recommended it for the 503A bulks list in July 2026, while injectable GHK-Cu was not reviewed), but that does not change the evidence gap, and TB-500 is explicitly banned in sport. [3] [6] [9] [10] [11]
How do TB-500 and GHK-Cu compare?
| Dimension | TB-500 (thymosin beta-4) | GHK-CuFavored |
|---|---|---|
| What it is [4] [7] | Synthetic thymosin beta-4 (43 amino acids) or a fragment of it; the identity of products sold as TB-500 is not verified. | Naturally occurring copper binding tripeptide (glycyl-histidyl-lysine) found in human plasma, saliva, and urine. |
| Evidence grade [3] [6] [13] | Animal only for the injectable. One human phase 2 eye drop trial (72 adults, dry eye) missed both primary endpoints; phase 1 intravenous studies in healthy volunteers tested safety only. | Human observational for topical use: small controlled cosmetic studies of creams in aged skin. No human data for injection. |
| Strongest animal evidence [1] [2] [5] | Rat full thickness wounds healed faster (reepithelialization up 42% at day 4 and 61% at day 7); improved cardiac function after coronary ligation in mice. | Faster skin wound healing in rats, mice, pigs, and dogs, plus hair follicle, bone, and gut healing in rodents. |
| Proposed mechanism [2] [4] [7] | Binds G-actin to drive cell migration and activates the ILK and Akt cell survival pathway; reduces inflammation and scarring in animals. | Delivers copper to cells, recruits repair cells, and increases collagen, elastin, and glycosaminoglycan synthesis; suppresses NF-kB and TNF-alpha in models. |
| Routes with human data [3] [6] | Topical eye drops only (investigational). Subcutaneous or intramuscular injection as sold has no human data. | Topical cream or serum only. Subcutaneous injection as sold has no human data. |
| FDA and compounding status [8] [9] [10] | Removed from 503A Category 2 on April 15, 2026; PCAC recommended adding it to the 503A bulks list in July 2026; no final rule yet. | Injectable nomination withdrawn, so no longer in Category 2, but not on the bulks list and not reviewed by PCAC. Topical is a lawful cosmetic ingredient when no drug claims are made. |
| WADA status [11] [12] | Prohibited at all times under S2; thymosin beta-4 and TB-500 are named on the list. | Not named. Injected GHK-Cu may fall under S0 as a non-approved substance, so its status is unclear; topical cosmetic use is not a recognized concern. |
| Typical cost [8] [10] | No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price. | Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. No lawful compounded price for injectable GHK-Cu, which is not on the 503A bulks list. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | TB-500 (thymosin beta-4) | GHK-Cu |
|---|---|---|
| Class | Synthetic version or fragment of thymosin beta-4, a 43 amino acid actin sequestering peptide present in nearly all human cells | Naturally occurring tripeptide (glycyl-histidyl-lysine) complexed with copper(II); found in human plasma, saliva, and urine |
| What it is | Copy or fragment of the repair protein thymosin beta-4: strong animal data, small human trials of the full protein, no trial of injected TB-500; WADA banned. | Copper binding three amino acid peptide with decades of skin and wound data: lawful and well studied in skin cosmetics, unapproved and untested as an injection. |
| Evidence | Evidence: Animal-only evidence | Evidence: Human observational evidence |
| FDA status | Regulatory: Under FDA review | Regulatory: Removed from Category 2 (Apr 2026) |
| Compounding | Removed from the FDA 503A Category 2 list (substances nominated for compounding that raise significant safety risks) on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding TB-500 to the 503A bulks list. As of the last verification date FDA has not published a final rule listing it, so it is not on the 503A bulks list and a 503A pharmacy has no federal basis to compound it from bulk; state boards cannot authorize what federal law does not. It is not an FDA approved drug and is not eligible for 503B outsourcing. Products sold as research chemicals are not lawful for human use. | GHK-Cu has two regulatory tracks. As a cosmetic ingredient in topical products it is lawfully marketed without FDA premarket approval, provided no drug claims are made. As an injectable drug it is not FDA approved and is not a component of any approved drug. GHK-Cu for injectable routes was nominated for the 503A bulks list and placed in 503A Category 2; the FDA Category 2 page current as of April 22, 2026 now lists it under bulk drug substances nominated but withdrawn, so it is no longer in Category 2 but is not on the bulks list and was not reviewed by the Pharmacy Compounding Advisory Committee in July 2026. Because it is not on the bulks list, a 503A pharmacy has no federal basis to compound injectable GHK-Cu from bulk, and state boards cannot authorize what federal law does not. Injectable products sold as research chemicals are not lawful for human use. |
| WADA | WADA: WADA prohibited | WADA: WADA status unclear |
| Routes | Subcutaneous or intramuscular injection (as sold), Topical eye drops (human dry eye trial, investigational), Topical to wound or intraperitoneal (animal studies) | Topical cream or serum (cosmetic use, the only form with human data), Subcutaneous injection (as sold; no human data), Topical, intraperitoneal, and systemic (animal studies) |
| Typical cost | No lawful compounded price: TB-500 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Last verified |
Has TB-500 been tested directly against GHK-Cu?
No published trial has compared TB-500 and GHK-Cu directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do TB-500 and GHK-Cu cost?
| Dimension | TB-500 (thymosin beta-4) | GHK-Cu |
|---|---|---|
| Typical cost | No lawful compounded price: TB-500 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Price detail | TB-500 (thymosin beta-4) price by channel | GHK-Cu price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Are TB-500 and GHK-Cu combined?
TB-500 and GHK-Cu are sold together in the premixed blends below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend pages cover what is in each product, the evidence for each ingredient, and legal status.
Frequently asked questions
Which is better for wound healing, TB-500 or GHK-Cu?
Both accelerate wound healing in animals, and neither has a human trial of the injectable form for wounds. Thymosin beta-4 has strong rat wound data, and GHK-Cu has animal wound data across several species plus human topical cosmetic studies. For a real wound, standard wound care comes first. [1] [5] [6]
Does the thymosin beta-4 eye drop trial support injected TB-500?
No. It tested 0.1% thymosin beta-4 eye drops for dry eye in 72 adults, and neither primary endpoint beat placebo. It is a different formulation, route, and indication from injected TB-500, and products sold as TB-500 may not even be the full length peptide. [3] [4]
Can athletes use either one?
TB-500 is explicitly prohibited: thymosin beta-4 and TB-500 are named under S2 of the WADA Prohibited List. GHK-Cu is not named, but injected use of a non-approved substance may fall under S0, so tested athletes should avoid the injectable. [11] [12]
Which is easier to get legally?
Topical GHK-Cu, which is sold over the counter as a cosmetic ingredient. Neither injectable has a lawful compounded path today: TB-500 was recommended for the 503A bulks list in July 2026 but awaits an FDA final rule, and injectable GHK-Cu is off Category 2 but not on the bulks list and was not reviewed. Research chemical vials of either are not lawful for human use. [8] [9] [10]
Conditions studied
From the blog
- Topical vs injectable GHK-Cu: what the evidence shows
Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and no lawful compounding path. Evidence, absorption, safety, and legality compared.
- Peptides for tendon recovery, ranked by human evidence
BPC-157, TB-500, GHK-Cu, PEG-MGF, and IGF-1 LR3 ranked by our evidence grades. None has a published human tendon trial. Here is the ranking, the reasoning, and what does have human data.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999PubMed 10469335, 1999
- [2]Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004PubMed 15565145, 2004
- [3]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
- [4]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
- [5]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018PubMed 29986520, 2018
- [6]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015PubMed 26236730, 2015
- [7]Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008PubMed 18644225, 2008
- [8]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [9]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [10]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 23). TB-500 vs GHK-Cu: evidence, cost, and legality. https://peptideagent.ai/compare/tb-500-vs-ghk-cu- HTML link
<a href="https://peptideagent.ai/compare/tb-500-vs-ghk-cu">TB-500 vs GHK-Cu: evidence, cost, and legality</a>, PeptideAgent, updated September 23, 2026.